002742.SHE Chongqing Sansheng Building Materials Co Ltd
- Market cap
- CNY 2.36B
- P/E
- -
- P/B
- 16.17x
- ROE
- -25.0%
- Dividend yield
- 0.72%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 002742.SHE undervalued?
Graham numberThe Graham number of Chongqing Sansheng Building Materials Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Chongqing Sansheng Building Materials Co Ltd fundamental analysis
No fundamental analysis for Chongqing Sansheng Building Materials Co Ltd yet.
Chongqing Sansheng Building Materials Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Chongqing Sansheng Building Materials Co Ltd
Chongqing Jiheng Pharmaceutical Co., Ltd. develops, produces and sells building materials and chemicals in China and internationally. It operates through two segments, Buildings Materials Chemical Industry; and Pharmaceutical Manufacturing. The company offers commercial concrete, water reducing agents, and expansion agents for industrial and civil buildings, highways, railways, bridges, tunnels, airports, water conservancy, and hydropower; and sulfuric acid is mainly used in…
Full company profileChongqing Sansheng Building Materials Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Chongqing Sansheng Building Materials Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.51B | 1.90B | 2.87B | 3.18B | 2.55B | 2.49B | 2.08B | 2.03B | 1.20B | 900M | 446M |
| Gross Profit | 366M | 460M | 671M | 635M | 586M | 405M | 308M | 380M | 197M | 141M | 59.3M |
| Operating Income | 141M | 211M | 174M | 174M | 114M | -307M | -204M | -276M | -568M | -99.1M | -10.3M |
| EBITDA | 259M | 406M | 463M | 476M | 429M | -26.1M | 64.1M | -32.2M | -307M | -142M | -13.6M |
| Net Income | 118M | 180M | 111M | 125M | 73.4M | -333M | -318M | -452M | -650M | -420M | -35.5M |
| EPS | 0.27 | 0.42 | 0.26 | 0.29 | 0.17 | -0.77 | -0.74 | -1.05 | -1.50 | -0.61 | -0.05 |
| Balance Sheet | |||||||||||
| Total Assets | 2.80B | 4.24B | 5.04B | 5.03B | 4.88B | 4.41B | 4.04B | 3.84B | 2.63B | 1.20B | 1.10B |
| Total Liabilities | 1.45B | 2.60B | 3.28B | 3.22B | 3.12B | 3.10B | 3.05B | 3.28B | 2.86B | 956M | 885M |
| Shareholders' Equity | 1.30B | 1.42B | 1.51B | 1.55B | 1.52B | 1.12B | 802M | 345M | -412M | 168M | 142M |
| Cash & Short-term Investments | 265M | 455M | 381M | 440M | 346M | 180M | 118M | 91.5M | 88.9M | 114M | 35.7M |
| Total Debt | 758M | 1.47B | 1.58B | 1.47B | 1.18B | 1.07B | 1.11B | 1.08B | 608M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 125M | 179M | -85.5M | 155M | 141M | 140M | 49.1M | -51.6M | -47.0M | -25.9M | - |
| Capital Expenditure | 246M | 310M | 203M | 411M | 94.6M | 98.8M | 44.2M | 46.5M | 58.4M | 9.42M | 2.62M |
| Free Cash Flow | -121M | -131M | -288M | -256M | 46.3M | 41.0M | 4.87M | -98.1M | -105M | -35.3M | -99.7M |
| Ratios | |||||||||||
| ROE | 9.0% | 12.7% | 7.4% | 8.0% | 4.8% | -29.7% | -39.6% | -130.9% | - | -249.2% | -25.0% |
| ROA | 4.2% | 4.3% | 2.2% | 2.5% | 1.5% | -7.6% | -7.9% | -11.8% | -24.8% | -35.1% | -3.2% |
| Net Profit Margin | 7.8% | 9.5% | 3.9% | 3.9% | 2.9% | -13.4% | -15.3% | -22.3% | -54.4% | -46.6% | -8.0% |
| Debt to Equity | 0.58x | 1.04x | 1.05x | 0.94x | 0.78x | 0.95x | 1.38x | 3.11x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Chongqing Sansheng Building Materials Co Ltd dividends
- Dividend yield
- 0.72%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jul 1, 2020
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 17.1M | 0.02 | - |
| 2024 | CNY 8.36M | 0.02 | - |
| 2023 | CNY 22.9M | 0.05 | - |
| 2022 | CNY 62.5M | 0.15 | - |
| 2021 | CNY 149M | 0.34 | - |
| 2020 | CNY 17.3M | 0.04 | 23.5% |
| 2019 | CNY 43.2M | 0.10 | 34.6% |
| 2018 | CNY 123M | 0.29 | 111.2% |
| 2017 | CNY 83.6M | 0.19 | 46.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 20:10 on Sep 8, 2017.
Who owns Chongqing Sansheng Building Materials Co Ltd
- Insiders 45.60%
- Institutions 0.03%
- Public & others 54.37%
- Shares outstanding 684M
- Free float 618M
Chongqing Sansheng Building Materials Co Ltd company profile
- Company name
- Chongqing Sansheng Building Materials Co Ltd
- Ticker
- 002742.SHE
- ISIN
- CNE100001WZ4
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Chemicals
- Employees
- 979
- Fiscal year end
- December
- Address
- No. 19-2, Yunquan Road, Chongqing, China, 400799
- Phone
- 86 23 6823 9069
- Website
- cqssgf.com
About Chongqing Sansheng Building Materials Co Ltd
Chongqing Jiheng Pharmaceutical Co., Ltd. develops, produces and sells building materials and chemicals in China and internationally. It operates through two segments, Buildings Materials Chemical Industry; and Pharmaceutical Manufacturing. The company offers commercial concrete, water reducing agents, and expansion agents for industrial and civil buildings, highways, railways, bridges, tunnels, airports, water conservancy, and hydropower; and sulfuric acid is mainly used in the production of fertilizers and in non-fertilizer acid enterprises such as fertilizers, chemicals, light industry, textile, steel, water reducer, and other non-fertilizer acid enterprises; and concrete admixtures. It also provides pharmaceutical intermediates, such as procaine hydrochloride, cefoxitin acid intermediates, chlorine intermediates, chloramphenicol intermediates, aztreonam intermediates, and orlistat intermediates used in antibiotic drugs, anti-hepatitis C drugs, diabetes drugs, benzathine penicillin and cefoxitin, procaine penicillin, and cosmetics; and API products, including acetaminophen, cloperidine hydrochloride, levofloxacin mesylate, benolate, and diphenhydramine hydrochloride. In addition, the company offers preparation products comprising compound acetaminophen and diphenhydramine tablets, clopidogrel hydrochloride tablets, clarithromycin sustained-release tablets, diclofenac sodium enteric-coated tablets, acetaminophen tablets, and famotidine tablets used in antipyretic and analgesic, antiviral, antibacterial, cough, allergy, local anesthesia; and famotidine, diclofenac sodium, nifedipine, acetaminophen, furosemide, norfloxacin used in clinical drugs to meet basic drug needs. The company was formerly known as Chongqing Sansheng Industrial Co.,Ltd. and changed its name to Chongqing Jiheng Pharmaceutical Co., Ltd. in June 2026. Chongqing Jiheng Pharmaceutical Co., Ltd. was incorporated in 2002 and is headquartered in Chongqing, China.
Chongqing Sansheng Building Materials Co Ltd management
3- Mr. Zhongqiang HuangGeneral Manager · born 1974
- Mr. Xiao ZhangBoard Secretary · born 1983
- Mr. Xuying GaoDeputy General Manager · born 1972